#DDHO2020 Emory Winship Debates and Didactics in Hematology and Oncology - Topics include breast, lung, colorectal, lymphoma, multiple myeloma and many other cancers
-
Madhav Dhodapkar, MBBS #DDHO2020
20:52
Overview of Immunology and Cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Fuad El Rassi, MD #DDHO2020
31:22
How to diagnose and manage hemoglobinopathies in the community practice presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Bassel El-Rayes, MD #DDHO2020
22:13
Sequencing therapies in borderline resectable pancreatic cancer presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Suresh Ramalingam, MD, FASCO #DDHO2020
22:47
Immunotherapy for NSCLC presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Taofeek Owonikoko, MD, PhD., MSCR #DDHO2020
23:25
Small cell lung cancer: Proven and promising options presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Nabil Saba, MD, FACP #DDHO2020
23:23
New advances in the treatment of head and neck cancers presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Hagop Kantarjian, MD #DDHO2020
19:18
Progress in frontline ALL therapy: Adding targeted agents to chemotherapy presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Sagar Lonial, MD, FACP #DDHO2020
20:07
Smoldering myeloma: State of the art presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
-
Pamela Blair Allen, MD, MSc #DDHO2020
17:42
Current and future front-line approaches for untreated HL presented at the Emory Winship Cancer Institute Debates and Didactics in Hematology and Oncology 2020
5 Live - Major conference takeways from experts in 5 minutes or less. Featuring new content from #ASCO20
-
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
4:24
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
-
Ajay K. Nooka, MD, MPH, FACP; Emory Winship Cancer Institute 5Live #ASCO20
4:59
Key Insights on DREAMM-6: Safety and tolerability of belantamab mafodotin in combination with bortezomib/dexamethasone in relapsed/refractory multiple myeloma (RRMM).
-
Othman Al-Sawaf, MD University Hospital, Cologne 5Live #ASCO20
3:48
Key Insights on Fixed-duration venetoclax-obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: Follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial
-
Martin Hutchings, MD, PhD Rigshospitalet, Copenhagen Denmark 5Live #ASCO20
6:23
Key Insights on Epcoritamab (GEN3013; DuoBody-CD3×CD20) to induce complete response in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL): Complete dose escalation data and efficacy results from a phase I/II trial.
-
Hope S. Rugo Professor of Medicine; Director, Breast Oncology and Clinical Trials Education; UCSF Comprehensive Cancer Center 5Live #ASCO20
6:58
"Key Insights on Alpelisib + fulvestrant in PIK3CA-mutated HR+/HER2– advanced BC previously treated with CDK 4/6 inhibitor + aromatase inhibitor (AI): BYLieve study results "
-
Lindsey Roeker, MD Memorial Sloan-Kettering Cancer Center 5Live #ASCO20
3:55
Key Insights on Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results
-
Thomas Powles, MD, MRCP; Barts Cancer Center 5Live #ASCO20
2:50
Key insights on IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).
-
Charles Herbaux, MD, MSc Centre Hospitalier Regional Universitaire de Lille, France 5Live #ASCO20
5:36
Key Insights on Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory diffuse large B-cell Lymphomas (R/R DLBCL): Primary analysis of a phase II trial from LYSA.
-
Hun Ju Lee, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO2020
5:08
Key Insights on Clinical activity of cirmtuzumab, an anti-ROR1 antibody, in combination with ibrutinib: Interim results of a phase Ib/II study in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL)
